Spread the news

Nuns stand in line while waiting to receive their first dose of China’s Sinovac Biotech Covid-19 vaccine during the mass vaccination programme for clergy in Jakarta February 25, 2021. — Reuters pic
Nuns stand in line while waiting to receive their first dose of China’s Sinovac Biotech Covid-19 vaccine during the mass vaccination programme for clergy in Jakarta February 25, 2021. — Reuters pic

Follow us on Instagram and subscribe to our Telegram channel for the latest updates.


JAKARTA, Oct 7 — Indonesia has approved a Covid-19 vaccine produced by a unit of China’s Chongqing Zhifei Biological Products for emergency use, its food and drug agency (BPOM) said today, the fourth Chinese vaccine cleared for use in the country.

BPOM chief Penny Lukito said the protein-recombinant vaccine, given three times in a three-month span, has an efficacy rate of about 81 per cent, with 77.47 per cent efficacy against the Delta variant, lower than other variants, she said.

Trials of the vaccine, Zifivax, were conducted in China, Uzbekistan, Pakistan, Ecuador and Indonesia, involving 28,000 people, with the efficacy based on any degree of severity.

Indonesia has also approved use of the Sinovac, Sinopharm, and CanSino vaccines.

Once Asia’s Covid-19 epicentre, Indonesia has vaccinated a fifth of its population of about 270 million people.

It has recorded more than 4.2 million coronavirus cases and 142,000 deaths overall, but average daily infections have fallen dramatically since the peak of its crisis in July.

Mahendra Suhardono, head of Jakarta Biopharmaceutical Industry, which is partnering with Zhifei, said Zifivax shots could be produced in Indonesia this year.

Zhifei and its unit, Anhui Zhifei Longcom Biopharmaceutical, did not immediately respond to requests for comment. — Reuters

Click to rate this post!
[Total: 0 Average: 0]

Spread the news
MI Contest
Previous articleEU says Facebook, YouTube remove less hate speech
Next articleGermany, Denmark repatriate women, children with ties to Islamic State

LEAVE A REPLY

Please enter your comment!
Please enter your name here